Cortendo Provides 2015 Half-Year Update On Corporate Progress
GÖTEBORG, Sweden & TREVOSE, Pa.--(BUSINESS WIRE)--Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, today announced an update on 2015 half-year corporate progress.
“The significant leadership experience and industry expertise of our Board of Directors and Management Team are tremendous assets as we continue to build a leading biopharmaceutical company focused on addressing unmet needs in rare diseases, including rare endocrine disorders such as Cushing’s Syndrome and acromegaly,” said Matthew Pauls, president and chief executive officer of Cortendo.
Help employers find you! Check out all the jobs and post your resume.
“The significant leadership experience and industry expertise of our Board of Directors and Management Team are tremendous assets as we continue to build a leading biopharmaceutical company focused on addressing unmet needs in rare diseases, including rare endocrine disorders such as Cushing’s Syndrome and acromegaly,” said Matthew Pauls, president and chief executive officer of Cortendo.
Help employers find you! Check out all the jobs and post your resume.